A new study in Nature Communications takes an initial step toward better understanding how KRAS drives immune evasion and demonstrates a lowering of the KRAS activity resulting in a more favorable immune environment to fight cancer.
Previous strategies to block the KRAS oncogene therapeutically have focused on counteracting its growth-promoting role in cancer. Read more . . .